10-K: Armata Pharma Advances Phage Therapies, Faces Going Concern Doubt

Armata Pharmaceuticals reports positive Phase 2a data for AP-SA02 in complicated S. aureus bacteremia, receives QIDP designation, and plans for Phase 3, but faces substantial doubt about its ability to continue as a going concern.

Summary

• Armata Pharmaceuticals is a late clinical-stage biotechnology company developing high-purity and potency, pathogen-specific bacteriophage therapeutics for antibiotic-resistant bacterial infections.
• The company has completed three Phase 2 clinical trials to date, focusing on AP-PA02 for chronic pulmonary infections (Cystic Fibrosis and Non-Cystic Fibrosis Bronchiectasis) and AP-SA02 for complicated S. aureus bacteremia.
• Positive topline data from the Phase 1b/2a diSArm study for AP-SA02 showed a statistically significant increase in clinical response rate (88% vs 58% placebo at Day 12) and 100% response at End of Study (EOS) compared to 25% non-response/relapse for placebo.
• The FDA confirmed that the Phase 2a diSArm study data supports advancement of AP-SA02 to Phase 3, and AP-SA02 received Qualified Infectious Disease Product (QIDP) designation, making it eligible for a five-year market exclusivity extension and Fast Track status.
• The Phase 3 study for AP-SA02 is anticipated to initiate in the second half of 2026, aiming to assess superiority over current standard of care and enroll approximately 450 patients.
• The Phase 1b/2a SWARM-P.a. study for AP-PA02 in cystic fibrosis demonstrated favorable safety, tolerability, and bacterial load reduction.
• The Phase 2 Tailwind study for AP-PA02 in non-cystic fibrosis bronchiectasis showed durable reduction of P. aeruginosa and a favorable safety profile, with a post-hoc analysis demonstrating statistically significant reduction in P. aeruginosa CFUs at Day 17 (P=0.05) and Day 24 (P=0.015).
• The company is exploring preclinical development of AP-PA03, an intravenously administered P. aeruginosa phage cocktail, for acute ventilator-associated pneumonia (VAP).
• Armata's Los Angeles cGMP manufacturing facility (10,000 sq ft) was formally commissioned in November 2025, capable of supporting Phase 3 and commercial production.
• As of December 31, 2025, the company had an accumulated deficit of $501.5 million and unrestricted cash and cash equivalents of $8.7 million, which are insufficient to fund operations for the next 12 months, raising substantial doubt about its ability to continue as a going concern.
• The net loss for the year ended December 31, 2025, was $173.8 million, an 818.8% increase from $18.9 million in 2024.
• The company secured $25.0 million in new term debt from Innoviva Strategic Opportunities LLC (Innoviva Sub) in 2025 ($10.0 million in March and $15.0 million in August) and entered into a Capital on Demand Sales Agreement for up to $100 million in common stock sales.
• The MTEC award from the U.S. Department of Defense was increased to $26.2 million, with the term extended to March 31, 2026.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed filing. While clinical progress for AP-SA02 and AP-PA02 is highly encouraging and regulatory designations are positive, the significant increase in net loss and the explicit 'going concern' warning raise serious financial viability concerns that overshadow the scientific advancements.

Positives

• Positive topline data from the Phase 1b/2a diSArm study for AP-SA02 in complicated S. aureus bacteremia, showing a statistically significant increase in clinical response rate (88% vs 58% placebo at Day 12; 100% vs 25% non-response/relapse for placebo at EOS).
• The FDA confirmed that the Phase 2a diSArm study data supports advancement of AP-SA02 to Phase 3.
• AP-SA02 received Qualified Infectious Disease Product (QIDP) designation, making it eligible for an additional five-year extension of Hatch-Waxman market exclusivity and Fast Track status.
• Positive results from the Phase 1b/2a SWARM-P.a. study for AP-PA02 in cystic fibrosis, demonstrating favorable safety, tolerability, and bacterial load reduction.
• Encouraging results from the Phase 2 Tailwind study for AP-PA02 in non-cystic fibrosis bronchiectasis, showing durable reduction of P. aeruginosa and a favorable safety profile.
• Formal commissioning of the Los Angeles cGMP manufacturing facility in November 2025, which supports future clinical trials and commercial production.
• Increased non-dilutive funding from the U.S. Department of Defense (MTEC award) to a total of $26.2 million.

Negatives

• Substantial doubt about the company's ability to continue as a going concern due to recurring losses and negative cash flows from operations.
• Accumulated deficit of $501.5 million as of December 31, 2025.
• Net loss of $173.8 million for the year ended December 31, 2025, an 818.8% increase from $18.9 million in 2024.
• Cash and cash equivalents of $8.7 million as of December 31, 2025, are insufficient to fund operations for the next 12 months.
• A significant loss of $121.0 million was recognized from the change in fair value of the Convertible Loan in 2025, compared to a $31.4 million gain in 2024.
• An impairment charge of $5.4 million was recognized in 2025 related to the Marina del Rey operating lease right-of-use asset.
• Interest expense increased by 54.4% to $16.6 million in 2025, primarily due to increased debt balances.

Risks

• There is substantial doubt about the company's ability to continue as a going concern, which may affect its ability to obtain future financing and may require it to curtail operations.
• The company will need substantial additional financing to develop its product candidates and implement operating plans; failure to obtain additional financing may delay or prevent the completion of development and commercialization.
• The company has incurred losses since its inception and anticipates continuing significant losses for the foreseeable future, making future profitability uncertain.
• Developing antibacterial agents using bacteriophage and synthetic phage technology is a novel approach, making it difficult to predict the time and cost of development, and no bacteriophage products have been approved in the United States or elsewhere.
• Results from interim, topline, and preliminary data, or preclinical studies and Phase 1 or 2 clinical trials, may not be predictive of later-stage clinical trials and are subject to audit and verification procedures that could result in material changes in the final data.
• The company must continue to develop manufacturing processes for its product candidates, and any delay or inability to do so would result in delays in clinical trials.
• Reliance on third parties to conduct clinical trials and obtain materials or supplies necessary for trials or manufacturing product candidates, with their failure to perform obligations in a timely or competent manner potentially delaying development and commercialization.
• Potential risks associated with future changes in laws and policies, including the availability of government funding for grants, staffing, and funding of regulatory agencies.
• The use or anticipated use of artificial intelligence (AI) technologies, including generative AI, by the company or third parties, may increase or create new operational risks.
• Business operations and current and future relationships with clinical site investigators, healthcare professionals, consultants, third-party payors, patient organizations, and customers will be subject to applicable healthcare regulatory laws, which could expose the company to penalties.
• Innoviva, the principal stockholder, beneficially owns greater than 50% of outstanding common stock, causing the company to be deemed a controlled company under NYSE rules, and Innoviva's interests may differ from other stockholders.
• The price of the company's securities has been volatile and may continue to be so, and purchasers could incur substantial losses.
• Raising additional capital may cause dilution to stockholders, restrict operations, and/or require relinquishing rights to technologies or product candidates.
• Unfavorable global economic conditions, whether brought about by material global crises, health epidemics, military conflicts or war, geopolitical and trade disputes, or other factors, may adversely affect the business and financial results.
• Operations could be disrupted by failure of information systems or by successful cyber-attacks.
• Inability to obtain and maintain patent protection for technology and product candidates, or if the scope of protection is not sufficiently broad, could allow competitors to develop and commercialize similar products.
• Third parties may initiate legal proceedings alleging intellectual property rights infringement, with uncertain outcomes that could significantly harm the business.
• Inability to protect intellectual property rights throughout the world, as filing, prosecuting, and defending patents globally is expensive, and foreign laws may offer less protection.
• Inability to protect the confidentiality of trade secrets, which would harm the business and competitive position.
• There is a high rate of failure inherent in drug discovery and development, and failure can occur at any point in the process, including in later stages after substantial investment.
• The company faces substantial competition from major pharmaceutical and biotechnology companies, which may result in others discovering, developing, or commercializing products before or more successfully.
• Product liability lawsuits against the company could cause substantial liabilities and limit commercialization of any products developed.
• Even if regulatory approval is received, the market may not be receptive to product candidates upon their commercial introduction, negatively affecting the ability to achieve profitability.
• Current and future healthcare reform measures may affect results of operations, including increasing government price controls and other public and private restrictions on pricing, reimbursement, and access for drugs.

Future Outlook

The company anticipates initiating a Phase 3 clinical study for AP-SA02 in complicated S. aureus bacteremia in the second half of 2026, with the belief that successful data could lead to AP-SA02 becoming a new standard of care and open opportunities for label expansion into uncomplicated S. aureus bacteremia and pediatric populations. Contingent upon securing sufficient funding, the company may resume clinical development of AP-PA02 for NCFB, potentially including a Phase 3 trial, and is actively exploring strategic partnerships for this program. Preclinical development of AP-PA03 for acute ventilator-associated pneumonia (VAP) is also being explored, with a potential IND filing contingent on funding. The company expects to continue incurring significant losses and will require additional capital to fund future operations and product development activities.

Management Comments

• We believe that phages represent a promising means to effectively treat bacterial infections as an alternative to broad-spectrum antibiotics, especially for patients with bacterial infections resistant to current standard of care therapies, including the multidrug-resistant or superbug strains of bacteria.
• We believe that we are uniquely advancing two distinct clinical candidates, referred to as AP-PA02 and AP-SA02, targeting two different bacterial pathogens with the potential to treat chronic pulmonary disease complicated by bacterial infection as well as acute systemic bacterial infection.
• We believe the data suggest that AP-PA02 alone is as effective as the combination therapy of phage and antibiotics in reducing P. aeruginosa CFUs in the lung.
• We believe the safety and tolerability of AP-PA02 offers a promising profile for treating chronically infected NCFB patients.
• We believe the learnings on dose-schedule regimens gained from the two completed Phase 2 studies position us to define a safe and promising biologic correlation for a Phase 3 definitive trial to evaluate inhaled AP-PA02 as an alternative to antibiotics in chronic pulmonary P. aeruginosa infection.
• We believe a key advantage of our phage manufacturing expertise is the purity profiles and the lot-to-lot consistency of our phage products, including AP-SA02.
• This is the first clear evidence in a randomized controlled trial of the efficacy of phage against a serious systemic pathogen that is responsible for significant morbidity and mortality in the United States.
• We believe that, if clinical superiority of AP-SA02 is demonstrated in the Phase 3 study for registration in adults with complicated S. aureus bacteremia, it is plausible the Phase 3 safety and efficacy data may potentially drive changes to infectious disease clinical treatment guidelines, requiring the use of AP-SA02 with antibiotics as new standard of care.
• We believe AP-SA02 could also have a meaningful impact in these indications [PJI and wound infections], particularly infections caused by MRSA.
• We believe Armata's phage platform has the potential to develop meaningful microbiome therapies utilizing the exquisite specificity offered by natural and/or synthetic bacteriophages.
• We believe that our facilities are adequate for our current and long-term needs. Additionally, we believe our McConnell facility, offering 10,000 square feet of manufacturing capacity, will allow us to pursue contract manufacturing opportunities for phage and potentially other advanced biologics.

Industry Context

StockSavvy.ai notes that Armata Pharmaceuticals operates in the critical and underserved market of antibiotic-resistant bacterial infections, a top 10 global public health threat. The company's focus on bacteriophage therapy positions it as a potential disruptor in an industry where novel antibiotic development has significantly declined over the last two decades. The market opportunity for anti-infective therapeutics is substantial, with global antibiotic sales projected to exceed $83 billion by 2032, highlighting the urgent need for new approaches like phage therapy to combat rising antimicrobial resistance (AMR) and healthcare-associated infections (HAIs).

Comparison to Industry Standards

• The 100% clinical response rate for AP-SA02 treated subjects at End of Study (EOS) in the Phase 1b/2a diSArm study compares favorably to the 25% non-responder rate reported in the literature for recent Phase 3 trials of standard of care (BAT alone) for complicated S. aureus bacteremia.
• The overall probability of success for anti-infective therapeutics from Phase 1 through regulatory approval is in the mid-teens (approximately 15-17%), reflecting the significant attrition risk in infectious disease drug development. Armata's advancement of two candidates (AP-PA02 and AP-SA02) through multiple Phase 2 trials and AP-SA02 to Phase 3, with QIDP and Fast Track designations, indicates progress beyond typical industry success rates for this stage.
• The company's in-house cGMP manufacturing capabilities for phage products are a differentiating factor, as many smaller biotech companies rely entirely on contract manufacturing, potentially offering greater control over purity, potency, and production efficiency compared to industry norms for novel biologics.

Corporate Governance

Legal Proceedings

• As of the date of this Annual Report, the company is not subject to any material legal proceedings.

Related Party Transactions

• Innoviva Strategic Opportunities LLC (Innoviva Sub), a wholly owned subsidiary of Innoviva, Inc., is the principal stockholder, owning 68.8% of the company's outstanding common stock as of December 31, 2025.
• Innoviva Sub holds 10,653,847 warrants to purchase common stock, with expiration dates extended to January 26, 2031.
• The company received $115.0 million in total debt financing from Innoviva Sub during 2023, March 2024, and March and August 2025.
• Entered into a $15.0 million loan (August 2025 Loan) with Innoviva Sub on August 11, 2025, bearing 14.0% annual interest and maturing January 11, 2029.
• Entered into a $10.0 million loan (March 2025 Loan) with Innoviva Sub on March 12, 2025, bearing 14.0% annual interest and maturing June 1, 2027.
• Entered into a $35.0 million loan (2024 Loan) with Innoviva Sub on March 4, 2024, bearing 14.0% annual interest and maturing June 1, 2027.
• Received a $30.0 million convertible loan from Innoviva Sub on January 10, 2023, bearing 8.0% annual interest and maturing June 1, 2027 (after amendments).
• On January 23, 2026, amendments were made to the March 2025, 2024, 2023 Credit Agreements and the Convertible Credit Agreement with Innoviva Sub, extending maturity dates to June 1, 2027, and amending related voting agreements.

Stakeholder Impact

• Shareholders face potential for significant dilution from future equity raises and stock price volatility due to the company's financial condition and need for additional capital. Innoviva's majority ownership limits the influence of other shareholders.
• Employees may face job insecurity if operations are curtailed due to funding issues, despite the company's commitment to competitive compensation and benefits.
• Future patients stand to benefit from novel bacteriophage therapies for life-threatening antibiotic-resistant infections, offering new treatment options where current antibiotics are failing.
• Creditors, particularly Innoviva Sub, have substantial exposure through various loans, which are secured by substantially all of the company's assets.
• Suppliers and partners, such as the Cystic Fibrosis Foundation and the U.S. Department of Defense (MTEC), are critical for funding and development, and their continued support is essential for the company's progress.

Next Steps

• Initiate Phase 3 clinical study for AP-SA02 in complicated S. aureus bacteremia in the second half of 2026.
• Submit a request for Fast Track Designation for AP-SA02 to the FDA.
• Address clinical and Chemistry, Manufacturing, and Controls (CMC) comments from the FDA for AP-SA02 Phase 3.
• Explore potential strategic partnerships to further advance the AP-PA02 program.
• Contingent on sufficient funding, resume clinical development of AP-PA02 for NCFB, potentially including a Phase 3 trial.
• Contingent on sufficient funding, file an IND application to initiate clinical development of AP-PA03 for VAP.
• Continue phage discovery efforts for other bacterial targets, such as Klebsiella pneumoniae.
• Actively seek a sub-tenant for the Marina del Rey Lease.
• Raise additional capital through equity offerings, debt financings, collaborative arrangements, government grants, or strategic financings.
• Conduct annual pay equity reviews for employees.

Key Dates

Recommendation

Despite promising clinical trial results and regulatory designations for its lead candidates, the company's explicit 'substantial doubt about its ability to continue as a going concern' due to significant recurring losses and insufficient cash to fund operations for the next 12 months presents an extremely high financial risk. The substantial increase in net loss and accumulated deficit, coupled with heavy reliance on related-party debt and the need for significant additional capital, indicates severe financial distress. While the science is compelling, the immediate financial outlook suggests a high probability of further dilution or operational curtailment, making the stock a 'sell' for risk-averse investors.

Keywords

bacteriophage therapy, antibiotic resistance, AP-SA02, Staphylococcus aureus bacteremia, AP-PA02, Pseudomonas aeruginosa, Cystic Fibrosis, Non-Cystic Fibrosis Bronchiectasis, QIDP, Fast Track, Phase 3 clinical trial, biotechnology, drug development, SEC filing, 10-K, Innoviva, going concern, clinical stage, infectious disease, cGMP manufacturing